Deane Retirement Strategies Inc. Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Deane Retirement Strategies Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 57.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 10,334 shares of the company’s stock after selling 14,197 shares during the period. Johnson & Johnson makes up approximately 1.2% of Deane Retirement Strategies Inc.’s holdings, making the stock its 20th largest position. Deane Retirement Strategies Inc.’s holdings in Johnson & Johnson were worth $1,854,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Hoylecohen LLC raised its holdings in Johnson & Johnson by 8.8% in the 4th quarter. Hoylecohen LLC now owns 136,846 shares of the company’s stock worth $23,410,000 after acquiring an additional 11,124 shares during the last quarter. True North Advisors LLC purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $6,808,000. Asset Allocation & Management Company LLC purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $1,436,000. Alberta Investment Management Corp raised its holdings in Johnson & Johnson by 23.8% in the 4th quarter. Alberta Investment Management Corp now owns 506,608 shares of the company’s stock worth $86,665,000 after acquiring an additional 97,467 shares during the last quarter. Finally, MKT Advisors LLC purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $508,000. 68.59% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.5 %

Shares of JNJ stock opened at $167.60 on Friday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The firm has a fifty day moving average price of $168.96 and a 200-day moving average price of $174.23. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. The company has a market cap of $440.65 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 2.95 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. During the same quarter in the previous year, the firm posted $2.48 EPS. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, equities analysts predict that Johnson & Johnson will post 10.7 earnings per share for the current year.

Johnson & Johnson declared that its board has authorized a share repurchase plan on Wednesday, September 14th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 1.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Citigroup decreased their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating for the company. SVB Leerink decreased their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. UBS Group cut their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $189.78.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.